During the last session, Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s traded shares were 1.24 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $2.08, reflecting an intraday loss of -0.48% or -$0.01. The 52-week high for the XERS share is $3.26, that puts it down -56.73 from that peak though still a striking 29.81% gain since the share price plummeted to a 52-week low of $1.46. The company’s market capitalization is $292.14M, and the average intraday trading volume over the past 10 days was 1.46 million shares, and the average trade volume was 2.35 million shares over the past three months.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Xeris Biopharma Holdings Inc (XERS) registered a -0.48% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.48% in intraday trading to $2.08, hitting a weekly high. The stock’s 5-day price performance is 1.46%, and it has moved by -31.58% in 30 days. Based on these gigs, the overall price performance for the year is 27.61%. The short interest in Xeris Biopharma Holdings Inc (NASDAQ:XERS) is 9.24 million shares and it means that shorts have 3.52 day(s) to cover.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Statistics show that Xeris Biopharma Holdings Inc has outperformed its competitors in share price, compared to the industry in which it operates. Xeris Biopharma Holdings Inc (XERS) shares have gone up 18.86% during the last six months, with a year-to-date growth rate more than the industry average at 15.56% against 8.20. In the rating firms’ projections, revenue will increase 12.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $41.81 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $45.1 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $33.2 million and $38.01 million respectively. In this case, analysts expect current quarter sales to grow by 25.90% and then jump by 18.70% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.13%. While earnings are projected to return 23.17% in 2024.
XERS Dividends
Xeris Biopharma Holdings Inc is due to release its next quarterly earnings on March 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
Xeris Biopharma Holdings Inc insiders own 3.87% of total outstanding shares while institutional holders control 44.82%, with the float percentage being 46.63%. Blackrock Inc. is the largest shareholder of the company, while 152 institutions own stock in it. As of Jun 29, 2023, the company held over 9.33 million shares (or 6.76% of all shares), a total value of $24.46 million in shares.
The next largest institutional holding, with 6.95 million shares, is of Vanguard Group Inc’s that is approximately 5.03% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $18.21 million.
Also, the Mutual Funds coming in first place with the largest holdings of Xeris Biopharma Holdings Inc (XERS) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 4.11 million shares. This amounts to just over 2.97 percent of the company’s overall shares, with a $10.76 million market value. The same data shows that the other fund manager holds slightly less at 3.04 million, or about 2.20% of the stock, which is worth about $6.91 million.
